NEW YORK, NY / ACCESSWIRE / September 10, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. (NASDAQ:AHCO)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/adapthealth-corp-f-k-a-dfb-healthcare-acquisitions-corp-loss-submission-form?prid=19488&wire=1
Lead Plaintiff Deadline: September 27, 2021
Class Period: November 11, 2019 - July 16, 2021

Allegations against AHCO include that: (i) AdaptHealth had misrepresented its organic growth trajectory by retroactively inflating past organic growth numbers without disclosing the changes, in violation of Securities and Exchange Commission regulations; (ii) accordingly, the Company had materially overstated its financial prospects; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Selectquote, Inc. (NYSE:SLQT)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/selectquote-inc-loss-submission-form?prid=19488&wire=1
Lead Plaintiff Deadline: October 15, 2021
Class Period: February 8, 2021 - May 11, 2021

Allegations against SLQT include that: (1) SelectQuote's 2019 cohort was underperforming; (2) as a result, the Company's financial results would be adversely impacted; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Sesen Bio, Inc. (NASDAQ:SESN)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=19488&wire=1
Lead Plaintiff Deadline: October 18, 2021
Class Period: December 21, 2020 - August 17, 2021

Allegations against SESN include that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong